Inhibition of FASN activity by TVB-2640 in patients with nonalcoholic steatohepatitis (NASH) shows protection, and its effects are being studied in phase IIb clinical trials (50). This evidence concerns the gene FASN and metabolic dysfunction-associated steatohepatitis.